Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Halts Three Non-CABG Trasylol Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision to discontinue trials in certain types of cancer patients was not related to safety concerns, firm maintains.

You may also be interested in...

New Labeling Limits Patient Population Of Bayer’s Trasylol

Changes are the result of September advisory committee meeting, concerns over renal dysfunction.

Bayer Suspends Senior Staffers For Failure To Disclose Trasylol Data To FDA

The company will publish findings of independent investigation, which could recommend corrective action plan.

Trasylol Not Associated With Renal/Heart Failure, MI, Stroke, Cmte. Says

FDA’s Cardiovascular & Renal Drugs Advisory Committee reiterate risk of renal dysfunction associated with aprotinin at its Sept. 21 meeting.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts